

## Special Issue

# Clinical Advances in Dermatology: Pathophysiology, Diagnosis and Treatment

### Message from the Guest Editors

The eruption of great therapeutic advances in our field, with the incorporation of biological drugs and molecules such as JAK (Janus Kinase) inhibitors, has advanced the knowledge of diagnosis thanks to new scales and results reported by patients that are being included in studies, clinical trials and randomized trials. New therapeutic targets and a better understanding of the pathophysiology of some immune-mediated diseases, such as psoriasis, atopic dermatitis, vitiligo, hidradenitis, urticaria or alopecia areata, have also emerged. In this issue, we will delve into the advances that are taking place in the different fields of clinical dermatology regarding these pathologies.

---

### Guest Editors

Dr. Ricardo Ruiz-Villaverde

Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain

Dr. Manuel Galán-Gutiérrez

Dermatology and Venereology, Hospital Universitario Reina Sofía, 14004 Córdoba, Spain

---

### Deadline for manuscript submissions

closed (25 May 2025)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/174828](https://mdpi.com/si/174828)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).